Estonia - Kiestonia - Ravimiamet

woerwag pharma gmbh & co. kg - sitagliptiin - õhukese polümeerikattega tablett - 50mg 98tk; 50mg 10tk; 50mg 28tk; 50mg 14tk; 50mg 100tk

Estonia - Kiestonia - Ravimiamet

woerwag pharma gmbh & co. kg - sitagliptiin - õhukese polümeerikattega tablett - 100mg 10tk; 100mg 98tk; 100mg 28tk; 100mg 100tk; 100mg 120tk; 100mg 14tk; 100mg 30tk

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

teva b.v.  - lamivudiin - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - lamivudiin teva pharma b. on näidustatud retroviiruste vastase kombineeritud ravi osana inimese immuunpuudulikkuse viiruse (hiv) -infektsiooniga täiskasvanutele ja lastele.

Estonia - Kiestonia - Ravimiamet

woerwag pharma gmbh & co. kg - sitagliptiin - õhukese polümeerikattega tablett - 25mg 14tk; 25mg 100tk; 25mg 10tk; 25mg 30tk; 25mg 28tk; 25mg 98tk

Estonia - Kiestonia - Ravimiamet

zaklady farmaceutyczne polpharma s.a. - nebivolool - tablett - 5mg 50tk; 5mg 100tk

Estonia - Kiestonia - Ravimiamet

zaklady farmaceutyczne polpharma s.a. - nebivolool - tablett - 10mg 50tk

Estonia - Kiestonia - Ravimiamet

esp pharma limited - rilusool - õhukese polümeerikattega tablett - 50mg 56tk

Estonia - Kiestonia - Ravimiamet

domes pharma - tramadool - tablett - 43,9mg 100tk; 43,9mg 10tk; 43,9mg 60tk

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

resilience biomanufacturing ireland limited - antigeen, mis sisaldab: a / vietnam / 1203/2004 (h5n1), gripivaktsiin (kogu virion, inaktiveeritud) - influenza, human; immunization; disease outbreaks - vaktsiinid - gripi profülaktika ametlikult pandeemia korral. pandeemilise gripi vaktsiini tuleks kasutada vastavalt ametlikele juhistele.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.